Omadacycline is a broad-spectrum aminomethylcycline bacterial protein synthesis inhibitor with activity against Gram-positive pathogens, Gram-negative bacilli, and resistant strains of Streptococcus pneumoniae. Results of this surveillance study support the continued use and development of omadacycline against key pathogens in the United States and European medical centers during 2018 (SENTRY). In vitro activity of omadacycline against recent (2018) bacterial pathogens from the United States and Europe obtained from skin and structure infection, respiratory, and urinary tract infections was evaluated. Omadacycline was very active against streptococci from SSSI, including 99.0%-99.3% of Streptococcus pyogenes 99.8% of Streptococcus anginosus S. pneumoniae 99.6% of group B streptococci (Table 1). Omadacycline was also active against 86.9% of Escherichia coli, 99.3% of Enterobacter aerogenes, and 93.6% of Escherichia coli isolates from RTI and 89.4% of Enterobacter aerogenes isolates from RTI (Table 2). Omadacycline was active against 93.3% of *Klebsiella pneumoniae* 86.2% of *Staphylococcus aureus* MRSA, and 86.2% of *Staphylococcus aureus* MSSA (Table 3). Results support the continued use and development of omadacycline against key pathogens in the United States and Europe.